Showing results (541-550 of 558) with videos related to
Sort By:
Pageof 56
JTO Clinical and Research Reports|January 31, 2024
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLCVanita Noronha, Nandini S Menon, Vijay Maruti Patil, et al.Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 24, 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS StudySolange Peters, Christian Schulz, Martin Reck, et al.JCO Global Oncology|December 12, 2023
Understanding the Impact of Population and Cancer Type on Tumor Mutation Burden Scores: A Comprehensive Whole-Exome Study in Cancer Patients From IndiaNishtha AjitSingh Tanwar, Richa Malhotra, Aiswarya Padmaja Satheesh, et al.Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.JCO Global Oncology|November 21, 2024
Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical RelevanceSatya Prakash Khuntia, Nilesh Mukherjee, Vyomesh Javle, et al.The Lancet. Oncology|April 3, 2020
Sustainable care for children with cancer: a Lancet Oncology CommissionRifat Atun, Nickhill Bhakta, Avram Denburg, et al.JCO Global Oncology|November 14, 2024
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III TrialKumar Prabhash, Chetan Deshmukh, Hemant Malhotra, et al.JCO Global Oncology|June 17, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based ChemoradiationVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.Pageof 56